» Articles » PMID: 38662264

Psychosocial Barriers and Facilitators for Cascade Genetic Testing in Hereditary Breast and Ovarian Cancer: a Scoping Review

Overview
Journal Fam Cancer
Publisher Springer
Specialty Oncology
Date 2024 Apr 25
PMID 38662264
Authors
Affiliations
Soon will be listed here.
Abstract

Despite increased awareness and availability of genetic testing for hereditary breast and ovarian cancer (HBOC) syndrome for over 20 years, there is still significant underuse of cascade genetic testing among at-risk relatives. This scoping review synthesized evidence regarding psychosocial barriers and facilitators of family communication and/or uptake of cascade genetic testing in relatives from HBOC families. Search terms included 'hereditary breast and ovarian cancer' and 'cascade genetic testing' for studies published from 2012-2022. Through searching common databases, and manual search of references, 480 studies were identified after excluding duplications. Each article was reviewed by two researchers independently and 20 studies were included in the final analysis. CASP, RoBANS 2.0, RoB 2.0, and MMAT were used to assess the quality of included studies. A convergent data synthesis method was used to integrate evidence from quantitative and narrative data into categories and subcategories. Evidence points to 3 categories and 12 subcategories of psychosocial barriers and facilitators for cascade testing: (1) facilitators (belief in health protection and prevention; family closeness; decisional empowerment; family support, sense of responsibility; self-efficacy; supportive health professionals); (2) bidirectional concepts (information; perception of genetic/cancer consequences; negative emotions and attitude); and (3) barriers (negative reactions from family and negative family dynamics). Healthcare providers need to systematically evaluate these psychosocial factors, strengthen facilitators and alleviate barriers to promote informed decision-making for communication of genetic test results and uptake of genetic testing. Bidirectional factors merit special consideration and tailored approaches, as they can potentially have a positive or negative influence on family communication and uptake of genetic testing.

Citing Articles

Returning genetic risk information for hereditary cancers to participants in a population-based cohort study in Japan.

Ohneda K, Suzuki Y, Hamanaka Y, Tadaka S, Shimada M, Hasegawa-Minato J J Hum Genet. 2025; 70(3):147-157.

PMID: 39825003 PMC: 11802448. DOI: 10.1038/s10038-024-01314-w.


Consumer-oriented (patient and family) outcomes from nursing in genomics: a scoping review of the literature (2012-2022).

Keels J, Thomas J, Calzone K, Badzek L, Dewell S, Murthy V Front Genet. 2024; 15:1481948.

PMID: 39678377 PMC: 11638212. DOI: 10.3389/fgene.2024.1481948.


Cascade genetic testing in hereditary cancer: exploring the boundaries of the Italian legal framework.

Varesco L, Di Tano F, Monducci J, Sciallero S, Turchetti D, Bighin C Fam Cancer. 2024; 24(1):9.

PMID: 39565467 DOI: 10.1007/s10689-024-00430-y.


Predictors and Interdependence of Quality of Life in a Random Sample of Long-Term Young Breast Cancer Survivors and Their Biological Relatives.

Ellis K, Koechlin H, Rudaz M, Gerido L, Hecht H, Jones C Cancer Med. 2024; 13(20):e70328.

PMID: 39470180 PMC: 11519995. DOI: 10.1002/cam4.70328.

References
1.
Kuchenbaecker K, Hopper J, Barnes D, Phillips K, Mooij T, Roos-Blom M . Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017; 317(23):2402-2416. DOI: 10.1001/jama.2017.7112. View

2.
Antoniou A, Pharoah P, Narod S, Risch H, Eyfjord J, Hopper J . Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003; 72(5):1117-30. PMC: 1180265. DOI: 10.1086/375033. View

3.
Childers C, Childers K, Maggard-Gibbons M, Macinko J . National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer. J Clin Oncol. 2017; 35(34):3800-3806. PMC: 5707208. DOI: 10.1200/JCO.2017.73.6314. View

4.
Caswell-Jin J, Zimmer A, Stedden W, Kingham K, Zhou A, Kurian A . Cascade Genetic Testing of Relatives for Hereditary Cancer Risk: Results of an Online Initiative. J Natl Cancer Inst. 2018; 111(1):95-98. PMC: 6335111. DOI: 10.1093/jnci/djy147. View

5.
Srinivasan S, Won N, Dotson W, Wright S, Roberts M . Barriers and facilitators for cascade testing in genetic conditions: a systematic review. Eur J Hum Genet. 2020; 28(12):1631-1644. PMC: 7784694. DOI: 10.1038/s41431-020-00725-5. View